Aptevo Therapeutics Inc. Net Income (Loss) Available to Common Stockholders, Basic
Aptevo Therapeutics Inc. (APVO) reported Net Income (Loss) Available to Common Stockholders, Basic of -$6.36 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-08-14
- Aptevo Therapeutics Inc. net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was -$6.36M.
- Aptevo Therapeutics Inc. net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was -$6.79M.
- Aptevo Therapeutics Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was -$5.90M.
- Aptevo Therapeutics Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was -$9.03M.
- Aptevo Therapeutics Inc. net income (loss) available to common stockholders, basic for fiscal 2025 was -$27.54M.
- Aptevo Therapeutics Inc. net income (loss) available to common stockholders, basic for fiscal 2024 was -$24.13M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$6.36M 10-Q · filed 2026-08-14 | -$13.15M 10-Q · filed 2026-08-14 | -$19.05M derived: sum of 3 quarters · filed 2026-08-14 | -$28.08M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$6.79M 10-Q · filed 2026-05-13 | -$12.69M derived: sum of 2 quarters · filed 2026-05-13 | -$21.72M derived: sum of 3 quarters · filed 2026-05-13 | -$27.92M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$5.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$14.93M derived: sum of 2 quarters · filed 2026-03-26 | -$21.13M derived: sum of 3 quarters · filed 2026-08-14 | -$27.54M 10-K · filed 2026-03-26 |
| 2025-09-30 | -$9.03M 10-Q · filed 2025-11-06 | -$15.23M derived: sum of 2 quarters · filed 2026-08-14 | -$21.64M 10-Q · filed 2025-11-06 | -$27.95M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$6.20M 10-Q · filed 2026-08-14 | -$12.61M 10-Q · filed 2026-08-14 | -$18.92M derived: sum of 3 quarters · filed 2026-08-14 | -$24.02M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$6.41M 10-Q · filed 2026-05-13 | -$12.72M derived: sum of 2 quarters · filed 2026-05-13 | -$17.82M derived: sum of 3 quarters · filed 2026-05-13 | |
| 2024-12-31 | -$6.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$11.41M derived: sum of 2 quarters · filed 2026-03-26 | -$24.13M 10-K · filed 2026-03-26 | |
| 2024-09-30 | -$5.10M 10-Q · filed 2025-11-06 | -$17.82M 10-Q · filed 2025-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B |